These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 18197877)

  • 1. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis.
    de Oliveira CP; Stefano JT; de Siqueira ER; Silva LS; de Campos Mazo DF; Lima VM; Furuya CK; Mello ES; Souza FG; Rabello F; Santos TE; Nogueira MA; Caldwell SH; Alves VA; Carrilho FJ
    Hepatol Res; 2008; 38(2):159-65. PubMed ID: 18197877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL.
    Oliveira CP; Cotrim HP; Stefano JT; Siqueira ACG; Salgado ALA; Parise ER
    Arq Gastroenterol; 2019 Aug; 56(2):184-190. PubMed ID: 31460584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of metformin and N-acetylcysteine with dietary control improves the biochemical and histological manifestations in rats with non-alcoholic fatty liver.
    El-Lakkany NM; Seif El-Din SH; Sabra AA; Hammam OA; Ebeid FA
    Res Pharm Sci; 2016 Oct; 11(5):374-382. PubMed ID: 27920819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The independent predictors of non-alcoholic steatohepatitis and its individual histological features.: Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment.
    Ballestri S; Nascimbeni F; Romagnoli D; Lonardo A
    Hepatol Res; 2016 Oct; 46(11):1074-1087. PubMed ID: 26785389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study.
    Huang MA; Greenson JK; Chao C; Anderson L; Peterman D; Jacobson J; Emick D; Lok AS; Conjeevaram HS
    Am J Gastroenterol; 2005 May; 100(5):1072-81. PubMed ID: 15842581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis.
    Le TA; Loomba R
    J Clin Exp Hepatol; 2012 Jun; 2(2):156-73. PubMed ID: 25755424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis.
    Sharma BC; Kumar A; Garg V; Reddy RS; Sakhuja P; Sarin SK
    J Clin Exp Hepatol; 2012 Dec; 2(4):333-7. PubMed ID: 25755455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S
    Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial.
    Shavakhi A; Minakari M; Firouzian H; Assali R; Hekmatdoost A; Ferns G
    Int J Prev Med; 2013 May; 4(5):531-7. PubMed ID: 23930163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of vitamin E treatment on peroxisome proliferator-activated receptor-alpha expression and insulin resistance in patients with non-alcoholic steatohepatitis: results of a pilot study.
    Yakaryilmaz F; Guliter S; Savas B; Erdem O; Ersoy R; Erden E; Akyol G; Bozkaya H; Ozenirler S
    Intern Med J; 2007 Apr; 37(4):229-35. PubMed ID: 17388862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical parameters response to weight loss in patients with non-alcoholic steatohepatitis.
    Abd El-Kader SM; Al-Shreef FM; Al-Jiffri OH
    Afr Health Sci; 2016 Mar; 16(1):242-9. PubMed ID: 27358638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.
    Jung KY; Cho SY; Kim HJ; Kim SB; Song IH
    J Clin Gastroenterol; 2014; 48(10):883-8. PubMed ID: 24440936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis.
    Manco M; Marcellini M; Devito R; Comparcola D; Sartorelli MR; Nobili V
    Int J Obes (Lond); 2008 Feb; 32(2):381-7. PubMed ID: 18087267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Weight Reduction on Histological Activity and Fibrosis of Lean Nonalcoholic Steatohepatitis Patient.
    Alam S; Jahid Hasan M; Khan MAS; Alam M; Hasan N
    J Transl Int Med; 2019 Sep; 7(3):106-114. PubMed ID: 31637181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study.
    Yoneda M; Fujita K; Nozaki Y; Endo H; Takahashi H; Hosono K; Suzuki K; Mawatari H; Kirikoshi H; Inamori M; Saito S; Iwasaki T; Terauchi Y; Kubota K; Maeyama S; Nakajima A
    Hepatol Res; 2010 Jun; 40(6):566-73. PubMed ID: 20412324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study.
    Laurin J; Lindor KD; Crippin JS; Gossard A; Gores GJ; Ludwig J; Rakela J; McGill DB
    Hepatology; 1996 Jun; 23(6):1464-7. PubMed ID: 8675165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.